図3 Overall and disease-free survival curves of patients with initially unresectable disease who underwent
Cancers | Free Full-Text | Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM
Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive
Survival analysis in hematologic malignancies: recommendations for clinicians | Haematologica
Comparison Overall survival and Disease free survival graph between two... | Download Scientific Diagram
Estimating progression-free survival in patients with glioblastoma using routinely collected data | Journal of Neuro-Oncology
The Importance of Disease-Free Survival as a Clinical Trial Endpoint: A Qualitative Study Among Canadian Survivors of Lung Cancer | The Patient - Patient-Centered Outcomes Research
Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study | Leukemia
Exploring the relationship between Overall Survival (OS), Progression Free Survival (PFS) and Objective Response Rate (ORR) in patients with advanced melanoma - ScienceDirect
Machine learning models predict overall survival and progression free survival of non-surgical esophageal cancer patients with chemoradiotherapy based on CT image radiomics signatures | Radiation Oncology | Full Text
Comparison of disease-free survival (DFS) and overall survival (OS)... | Download Scientific Diagram
Cancers | Free Full-Text | Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma
PPT - Overall Survival and Progression-Free Survival PowerPoint Presentation - ID:4064400
Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic
Disease Free Survival - an overview | ScienceDirect Topics
Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials - London - 2017 - Cancer - Wiley
Overall survival vs disease-free survival and other surrogate endpoints - survival-analysis - Datamethods Discussion Forum
Disease-Free Survival As a Clinical Trial Endpoint: Does It Matter, and to Whom? | ASCO Daily News
Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed | Nature Reviews Clinical Oncology
Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive
JCM | Free Full-Text | Time to Surgery Does Not Affect Overall or Disease-Free Survival of Patients with Primary Resectable PDAC
Disease-free survival landmark analysis: a potential critical endpoint in triple-negative breast cancer | Experimental Hematology & Oncology | Full Text
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine | NEJM
Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed | Nature Reviews Clinical Oncology
The Importance of Disease-Free Survival as a Clinical Trial Endpoint: A Qualitative Study Among Canadian Survivors of Lung Cancer | The Patient - Patient-Centered Outcomes Research
